# Open-label Treatment in Cushing's Syndrome

> **NCT03621280** · PHASE3 · COMPLETED · sponsor: **Cortendo AB** · enrollment: 51 (actual)

## Conditions studied

- Cushing Syndrome
- Cushing Disease

## Interventions

- **DRUG:** Levoketoconazole

## Key facts

- **NCT ID:** NCT03621280
- **Lead sponsor:** Cortendo AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03621280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03621280, "Open-label Treatment in Cushing's Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03621280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*